title: [Medical management of cholangiocarcinomas in 2015].
abstract: Cholangiocarcinoma is a rare malignancy carrying a poor prognosis. Most patients are diagnosed with advanced-stage disease and are then ineligible for surgical resection, which is the only potentially curative therapeutic modality. The aim of this article is to provide an up-to-date review of medical management of patients with cholangiocarcinoma. The benefit of adjuvant therapy in patients undergoing curative-intent surgery is under evaluation. Combination chemotherapy with gemcitabine and platinum is the standard first-line treatment for patients with advanced cholangiocarcinoma. Targeted agents are not currently recommended due to limited data on use in this setting. The role of second-line chemotherapy is not established in advanced cholangiocarcinoma. Identification of predictive and prognostic markers to select patients who could benefit from second-line therapy is a major issue. A better understanding of the biological and molecular mechanisms underlying the carcinogenesis and the phenotypic heterogeneity of cholangiocarcinoma may path the way of new therapeutic strategies.
authors.affiliation: Assistance publique-Hôpitaux de Paris (AP-HP), université Paris Est Créteil (UPEC), hôpital Henri-Mondor, service d'oncologie médicale, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
authors.forename: Grégoire
authors.initials: G
authors.lastname: Marret
authors.affiliation: Assistance publique-Hôpitaux de Paris (AP-HP), université Paris Est Créteil (UPEC), hôpital Henri-Mondor, service d'oncologie médicale, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France. Electronic address: cindy.neuzillet@gmail.com.
authors.forename: Cindy
authors.initials: C
authors.lastname: Neuzillet
authors.affiliation: Assistance publique-Hôpitaux de Paris (AP-HP), université Paris Est Créteil (UPEC), hôpital Henri-Mondor, service d'oncologie médicale, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
authors.forename: Benoît
authors.initials: B
authors.lastname: Rousseau
authors.affiliation: Assistance publique-Hôpitaux de Paris (AP-HP), université Paris Est Créteil (UPEC), hôpital Henri-Mondor, service d'oncologie médicale, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Tournigand
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001650:Bile Duct Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D018281:Cholangiocarcinoma / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007269:Injections, Intra-Arterial / Q000379:methods; D059016:Tumor Microenvironment
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: Anti-EGFR; Antiangiogenics; Antiangiogéniques; Biliary tract carcinoma; Cancer des voies biliaires; Chemotherapy; Chimiothérapie; Cholangiocarcinoma; Cholangiocarcinome; Targeted therapies; Thérapies ciblées